Image of Gail H Cassell

Gail H Cassell, PhD

Senior Lecturer on Global Health and Social Medicine

Dr. Cassell is vice president for TB Drug Development at the Infectious Disease Research Institute in Seattle, Washington, professor emeritus and former chair, Department of Microbiology, University of Alabama at Birmingham, and former vice president for scientific affairs and distinguished Lilly research scholar for infectious diseases at Eli Lilly and Company in Indianapolis, Indiana. She founded the Forum on Drug Discovery, Development and Translation, which she continues to co-chair, at the Institute of Medicine. She has a distinguished record of national service with the National Academy of Sciences, National Institutes of Health, Centers for Disease Control, and several other national and international institutions.

Affiliations:

Division of Global Health Equity, Brigham and Women's Hospital

Dr. Cassell is a leader on efforts to address multidrug-resistant tuberculosis (MDRTB). She and Barry Bloom, former dean of Harvard School of Public Health, co-lead an Institute of Medicine project on drug supply chain issues related to MDRTB. She actively advises numerous government agencies, NGOs, and foundations on the scale-up of MDRTB diagnosis and treatment in endemic areas around the world, including in Russia. Dr. Cassell is advising the GHSM Sentinel Project on pediatric drug-resistant tuberculosis, a global partnership that aims to develop and deploy evidence-based strategies to prevent child deaths from drug-resistant tuberculosis.

Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa.
Authors: Authors: Loveday M, Wallengren K, Brust J, Roberts J, Voce A, Margot B, Ngozo J, Master I, Cassell G, Padayatchi N.
Int J Tuberc Lung Dis
View full abstract on Pubmed
Shifting gears to control drug-resistant tuberculosis.
Authors: Authors: Berkelman RL, Cassell GH, Whitney EA, Keshavjee S.
Clin Infect Dis
View full abstract on Pubmed
Comparative genome analysis of 19 Ureaplasma urealyticum and Ureaplasma parvum strains.
Authors: Authors: Paralanov V, Lu J, Duffy LB, Crabb DM, Shrivastava S, Methé BA, Inman J, Yooseph S, Xiao L, Cassell GH, Waites KB, Glass JI.
BMC Microbiol
View full abstract on Pubmed
Extensive horizontal gene transfer in ureaplasmas from humans questions the utility of serotyping for diagnostic purposes.
Authors: Authors: Xiao L, Paralanov V, Glass JI, Duffy LB, Robertson JA, Cassell GH, Chen Y, Waites KB.
J Clin Microbiol
View full abstract on Pubmed
Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence.
Authors: Authors: Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, Weyer K, Lancaster J, Van der Walt M.
PLoS One
View full abstract on Pubmed
Detection and characterization of human Ureaplasma species and serovars by real-time PCR.
Authors: Authors: Xiao L, Glass JI, Paralanov V, Yooseph S, Cassell GH, Duffy LB, Waites KB.
J Clin Microbiol
View full abstract on Pubmed
Deficient immune response to Mycoplasma pneumoniae in childhood asthma.
Authors: Authors: Atkinson TP, Duffy LB, Pendley D, Dai Y, Cassell GH.
Allergy Asthma Proc
View full abstract on Pubmed
Ureaplasma parvum or Mycoplasma hominis as sole pathogens cause chorioamnionitis, preterm delivery, and fetal pneumonia in rhesus macaques.
Authors: Authors: Novy MJ, Duffy L, Axthelm MK, Sadowsky DW, Witkin SS, Gravett MG, Cassell GH, Waites KB.
Reprod Sci
View full abstract on Pubmed
Grand challenges for psychiatric drug discovery: a perspective.
Authors: Authors: Brady LS, Giffin RB, Woodcock J, Cassell GH, Holmes EW.
Neuropsychopharmacology
View full abstract on Pubmed
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever.
Authors: Authors: Hensley LE, Stevens EL, Yan SB, Geisbert JB, Macias WL, Larsen T, Daddario-DiCaprio KM, Cassell GH, Jahrling PB, Geisbert TW.
J Infect Dis
View full abstract on Pubmed